Pharmaceutical & Life Sciences News

Medicare Boost for New Cancer Therapy Leaves Hospitals Short

April 25, 2019, 9:45 AM

The government isn’t bending to the high prices set by Novartis AG and Gilead Sciences for two cutting-edge cancer treatments even though Medicare plans to cover more of the cost.

“For these two therapies right now, it’s a bit of a standoff,” Stacie Dusetzina, an associate professor in health policy and cancer research at Vanderbilt University Medical Center, said April 24. “The administration has been very vocal about not changing how they pay for everything to try to accommodate very high price tags of treatment.”

The Centers for Medicare & Medicaid Services released a suite of payment proposals April 23...

To read the full article log in. To learn more about a subscription click here.